HomeDNA • NYSE
add
Ginkgo Bioworks Holdings Inc
Previous close
$8.14
Day range
$7.68 - $8.13
Year range
$5.26 - $74.00
Market cap
382.03M USD
Avg Volume
1.14M
P/E ratio
-
Dividend yield
-
Primary exchange
NYSE
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 89.05M | 60.65% |
Operating expense | 129.30M | -45.83% |
Net income | -56.40M | 81.38% |
Net profit margin | -63.34 | 88.41% |
Earnings per share | — | — |
EBITDA | -35.09M | 79.25% |
Effective tax rate | 0.66% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 616.21M | -41.27% |
Total assets | 1.48B | -26.92% |
Total liabilities | 682.94M | -11.73% |
Total equity | 797.94M | — |
Shares outstanding | 53.08M | — |
Price to book | 0.54 | — |
Return on assets | -8.41% | — |
Return on capital | -10.33% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -56.40M | 81.38% |
Cash from operations | -103.50M | -40.72% |
Cash from investing | -10.20M | -201.69% |
Cash from financing | -465.00K | -47.62% |
Net change in cash | -114.20M | -47.47% |
Free cash flow | -61.72M | -217.87% |
About
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
CEO
Founded
2008
Headquarters
Website
Employees
1,218
